| Drug Name |
Carfilzomib |
| Drug ID |
BADD_D00367 |
| Description |
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392] |
| Indications and Usage |
Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. |
| Marketing Status |
Prescription |
| ATC Code |
L01XG02 |
| DrugBank ID |
DB08889
|
| KEGG ID |
D08880
|
| MeSH ID |
C524865
|
| PubChem ID |
11556711
|
| TTD Drug ID |
D00UVA
|
| NDC Product Code |
50384-0180; 52076-6251; 76075-103; 50384-0230; 54893-0037; 76055-0035; 63552-009; 16436-0116; 63552-035; 50384-0260; 55111-985; 11722-059; 50384-0220; 50384-0210; 50384-0190; 67262-0010; 76075-102; 50384-0240; 42385-731; 76075-101 |
| Synonyms |
carfilzomib | PR-171 | PR171 | Kyprolis |
